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Abstract
Serodiscordant couples play an important role in maintaining the global HIV epidemic. This 
review summarizes biobehavioral and biomedical HIV prevention options for serodiscordant 
couples focusing on advances in 2013 and 2014, including World Health Organization guidelines 
and best-evidence for couples counseling, couples-based interventions, and the use of antiviral 
agents for prevention. In the past few years marked advances have been made in HIV prevention 
for serodiscordant couples and numerous ongoing studies are continuously expanding HIV 
prevention tools, especially in the area of pre-exposure prophylaxis. Uptake and adherence to 
antiviral therapy remains a key challenge. Additional research is needed to develop evidence-
based interventions for couples, and especially for male-male couples. Randomized trials have 
demonstrated the prevention benefits of antiretroviral-based approaches among serodiscordant 
couples; however, residual transmission observed in recognized serodiscordant couples represents 
an important and resolvable challenge in HIV prevention.
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INTRODUCTION HIV SERODISCORDANT COUPLES: BACKGROUND, 
DEFINITIONS AND GUIDELINES
I. What is a serodiscordant couple?
The term “serodiscordant couple” refers to an intimate partnership in which one person is 
HIV-positive and the other is HIV-negative. In research studies, the “couple” relationship is 
typically defined by marital, cohabitating or co-parenting status or by length of relationship 
(e.g. minimum of 3-6 months), intention to stay together, or reporting a certain minimum 
number of sexual acts with this partner within a given timeframe [1]. A number of 
considerations exist for research and prevention among serodiscordant couples. In general, 
the couple does not stay discordant forever. By definition, the HIV-negative partner is 
considered as “exposed and uninfected”. Indeed, trying to understand the basis for apparent 
protection from HIV has been the source of much investigation [2]. In addition, “stable 
couples” are more fluid than the definition belies: they may temporarily or permanently 
dissolve, reunite, or involve outside others (i.e. concurrent sexual relationships by one or 
both of the partners). Furthermore, couples themselves interpret serodiscordance differently 
in different cultural or relationship contexts [3]. For example, couples interviewed in 
Uganda understood serodiscordance to mean undetected infection or HIV immunity among 
the HIV-negative partner [4].
Serodiscordant couples play a role in maintaining the global HIV epidemic. In surveillance 
studies, it is common to detect large numbers of serodiscordant couples: in concentrated 
epidemics, 0 to 6% of all couples may be serodiscordant, while in generalized epidemics this 
figure ranges from 9 to 17% [5]. HIV transmission within serodiscordant couples can 
contribute substantially to the overall burden of disease. In high prevalence areas like sub-
Saharan Africa, approximately half of HIV-positive persons have negative partners, and in 
low prevalence settings, this proportion may be as high as 75% [5]. A 2013 modeling study 
among 20 countries in sub-Saharan Africa estimated that 29% (range 10-52%) of new 
infections occurred within stable serodiscordant couples [6]. An earlier estimate for Zambia 
alone attributed 60.3 to 94.2% of all new heterosexual HIV infections to serodiscordant 
married or cohabitating couples [7]. Among MSM, an estimated 33 to 67% of new HIV 
infections occur within a primary partnership [8, 9].
In this review we summarize biobehavioral and biomedical HIV prevention options for 
serodiscordant couples focusing on advances in 2013 and 2014 (up to July 1). We begin 
with the recent World Health Organization (WHO) guidelines for serodiscordant couples, 
review the evidence for couples counseling, couples-based interventions, and use of antiviral 
agents as a prevention strategy and briefly address well-accepted forms of prevention 
including screening and treatment for other sexually transmitted infections (STI) and male 
circumcision.
II. International guidelines for serodiscordant couples
Serodiscordant couples have attracted a substantial amount of attention for HIV prevention 
activities - so much so that they have been defined as a “special population” whose care is 
outlined in multiple sets of normative guidelines beginning with the August 2011 PEPFAR 
Muessig and Cohen Page 2






















guidelines [10] and the April 2012 WHO guidelines for serodiscordant couples (Figure 1) 
[11, 12]. These guidelines include a strong recommendation for Couples HIV Testing and 
Counseling (CHTC) with support for mutual status disclosure, initiation of antiretroviral 
therapy (ART) irrespective of CD4 cell count or clinical disease stage for people in 
serodiscordant partnerships, and consideration under some circumstances for the use of pre-
exposure prophylaxis (PrEP) for HIV-uninfected persons in serodiscordant partnerships 
[12]. By year-end 2012, 19 out of 70 countries (27%) had national ART treatment guidelines 
that matched the WHO’s treatment guidelines for serodiscordant couples [13]. An updated 
2014 review of 124 low and middle income countries found that only 26% countries had 
comparable guidelines in place [14].
PREVENTING HIV TRANSMISSION WITHIN SERODISCORDANT COUPLES
I. Biobehavioral approaches
Couples HIV Testing and Counseling: It works—Worldwide, 30 to 70% of HIV-
positive persons remain unaware of their status [15]. Over 20 years of history shows 
evidence that Couples HIV Testing and Counseling (CHTC) increases testing, increases 
condom use and decreases seroconversion [16, 17]. In the Partners in Prevention HSV/HIV 
Transmission randomized controlled trial (RCT) (South Africa, 2004 – 2008) knowledge of 
one’s HIV status and of serodiscordance within the relationship both led to sustained 
reductions in condomless sex [18]. Furthermore, within the two largest trials of ART 
treatment as prevention - the Partners Preexposure Prophylaxis (PrEP) Study and the HPTN 
052 study - anticipated transmission among couples was greatly reduced with regular testing 
and intense couples counseling. These studies brought linked HIV transmission events in the 
study control arms to under 2 events per 100 person years, representing a new standard for 
prevention in the absence of biomedical intervention [19, 20].
In a recent review, Medley and colleagues catalogue the benefits of CHTC to serodiscordant 
couples including: decreased transmission within all sexual partners, safer conception, 
increased psychosocial support, decreased unplanned pregnancy, and increased uptake of 
and adherence to family planning services, ART, and prevention of mother to child 
transmission services (PMTCT) [21]. In addition to HIV testing, services that can be 
provided or referred via CHTC include earlier initiation of ART, reproductive health 
services, risk reduction counseling and condom distribution, STI screening and treatment, 
repeat HIV-testing for HIV-negative partners, and voluntary medical male circumcision for 
HIV-negative male partners [21]. Reproductive health services for serodiscordant couples 
who wish to conceive may include pre-conception counseling, PMTCT and services such as 
sperm washing with intrauterine insemination or In Vitro Fertilization [22].
Despite proven benefits, demand for CHTC remains low. One study from Rakai, Uganda, 
found that uptake of CHTC did not exceed 29% any year from 2003 to 2009 [23]. 
Additionally, CHTC has traditionally not been available for MSM couples [24] though 
recent studies demonstrate that it is acceptable and feasible among diverse MSM 
populations in the U.S., Africa and China [25-27]. The U.S. CDC is currently developing 
MSM-specific CHTC training guidelines [24].
Muessig and Cohen Page 3






















Additional advances that are changing the landscape of couples-based testing include the 
July 2012 U.S. Food and Drug Administration’s (FDA) approval of a rapid HIV self-test, 
OraQuick®, which may facilitate in-home, self-guided couples testing. eSTAMP is a current 
CDC funded study to explore MSM’s use of OraQuick® and Sure Check ® (a comparable 
HIV self-test) (http://clinicaltrials.gov/show/NCT02067039). Risk estimators and 
assessment tools are also under development to help couples make informed sexual health 
decisions [28] and help care providers identify high-risk serodiscordant couples to guide 
decisions around use of ART and PrEP [29].
Couples-based interventions—Beyond CHTC, interventions designed specifically for 
couples may be more effective than individual-focused interventions alone at reducing 
transmission risk among serodiscordant couples [30]. These interventions promote 
established risk reduction behaviors (e.g. condom use, decreasing number of partners) as 
well as couple-relevant strategies including communication and negotiation skills. Although 
commonly delivered at the dyadic level, group-level couples-focused interventions are also 
effective. For example, the Zambia NOW2 project compared a couples-focused intervention 
delivered in pairs or in gender-matched groups (e.g. all females with female counselor). 
Both study conditions found increased willingness, acceptability, and use of male and 
female condoms, decreased intimate partner violence and increased positive communication 
[31]. Couples-based initiatives focused on peer support are also being explored, such as the 
serodiscordant Couples’ Clubs that are being promoted in Uganda [32].
Couples-based biobehavioral interventions remain an underdeveloped resource. As of April 
2014, within the U.S. CDC’s HIV/AIDS Prevention Research Synthesis Project for 
Evidence Based Interventions (EBIs), out of 84 risk reduction EBIs, none focused on MSM 
couples and only two addressed heterosexual couples [33]: Connect 2 provided couples 
counseling for low-income drug users in New York City and significantly reduced 
unprotected vaginal sex acts over a 12 month period with both the study partner and outside 
partners [34]. Adaptations of Connect have shown preliminary efficacy in groups as diverse 
as young, heterosexual couples in South Africa [35] and methamphetamine-involved Black 
MSM couples in the U.S. [36]. The second EBI, Eban, delivered an intervention tailored for 
African American heterosexual serodiscordant couples in four U.S. cities and found 
increased consistent condom use and decreased number of unprotected sex acts [37]. Eban is 
currently being scaled-up through a community-based implementation trial [38].
A recent systematic review identified 27 biobehavioral interventions for serodiscordant 
couples [1]. Thirteen studies focused on psycho-educational skills building but the majority 
had insufficient power to demonstrate change in a biological outcome. The primary elements 
of skills-building interventions included HIV/STI knowledge, condom use, couple-focused 
communication, negotiation, problem-solving, goal setting, addressing relationship power 
imbalances and decision making, strategies for maintaining healthy relationships, and 
specific focus on negotiating unsafe injection practices among people who inject drugs. An 
additional 13 studies focused on CHTC for heterosexual couples and one study focused on 
medication adherence for heterosexual and MSM couples [1].
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The limited number of interventions for MSM couples [1, 24] and high prevalence of 
undiagnosed serodiscordant MSM couples [39] argues for increasing MSM couples-based 
interventions. A pilot test adapting Connect for use with methamphetamine-involved Black 
MSM couples shows promise but needs large-scale testing [36]. New interventions should 
be generated in close collaboration with the specific target communities to work within 
social and sexual norms. For example, one study found that serodiscordant MSM couples 
who adopt a “we” (versus “me”) orientation have less unprotected insertive and receptive 
anal intercourse [40]. Other qualities of MSM couples such as relationship commitment, 
relationship intimacy and sexual satisfaction are associated with risk taking behavior [41] 
and may be relevant constructs for MSM-tailored couples interventions. A range of 
seroadaptive strategies for HIV prevention have also evolved within the MSM and 
transgender community including serosorting, seropositioning, and negotiated safety [24]. A 
WHO evidence based review of serosorting for MSM and transgender persons recommends 
the practice only “under specific circumstances as a harm reduction strategy” but 
emphasizes the limits of current evidence and specifies that condom use is recommended 
over serosorting [42].
II. Biomedical approaches
Medical male circumcision—Male circumcision is one of the most effective biomedical 
interventions for preventing HIV acquisition in heterosexual men as established through 
three RCTs and a number of observational studies [43]. The reduction in HIV acquisition 
among heterosexual circumcised men is approximately 60% [44]. Within heterosexual 
serodiscordant couples where the male is HIV-negative, medical male circumcision is 
recommended [42]. However, circumcision is not currently recommended for HIV-positive 
men within serodiscordant relationships or MSM [42]. Two earlier meta-analyses found 
moderate protective benefit of circumcision among MSM who primarily practice insertive 
anal intercourse [45, 46] but recent individual studies [47, 48] and an updated WHO 
evidence review have not confirmed that the benefits of circumcision outweigh potential 
risks for MSM [42].
Testing and treatment for sexually transmitted infections—Sexually transmitted 
infections (STI) are common among people living with HIV [49] and amplify transmission 
[50]. Both partners within serodiscordant couples should be regularly tested as STI may 
increase both transmission and acquisition vulnerability for HIV [51, 52]. Regular screening 
and follow-up treatment should be provided to both the HIV-negative and HIV-positive 
partner to maximize prevention benefit.
Antiretroviral Treatment as Prevention (TasP) (Table 1)—A key element in the 
serodiscordant couples’ prevention strategy is the use of antiviral agents as either pre-
exposure prophylaxis (PrEP) or in the form of treatment as prevention (TasP) [53]. Blood, 
viral load [54] and genital tract viral load [55] of the HIV-positive index case predict 
transmission probability. In 11 out of 13 observational studies [53, 56, 57] and one large 
RCT [19], antiretroviral treatment reduced HIV transmission within serodiscordant couples, 
presumably by suppressing viral replication (Table 1). The HPTN 052 study provided an 
absolute number to the prevention benefits of early ART among serodiscordant heterosexual 
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couples – a reduction in transmission of 96% [19]. A meta-analysis of heterosexual 
serodiscordant couple studies where the HIV-positive partner is on ART and virally 
suppressed found 0 transmissions per 100 person years [58], while another similar review of 
partners on combination ART for at least 6 months found a per act transmission risk 
estimated at between 1 and 13 per 100,000 sex acts whether or not full viral suppression was 
achieved [59].
A meta-analysis of 50 publications related to discordant couples studies found a 91% (79 – 
96%) reduction in per-partner HIV-1 incidence among couples using ART [60]. In perhaps 
the largest sample to date, a retrospective cohort analysis of 38,862 serodiscordant 
heterosexual couples in the People’s Republic of China found a 26% relative reduction in 
transmission among those on ART [61]. Numerous confounders and the observational 
nature of this study suggest that it may be a conservative estimate of the actual transmission 
prevention benefit of ART [62].
There are concerns that controlled trial environments overestimate the “real-world” 
effectiveness of TasP. We have previously reviewed this topic in detail [63]. Tanser et al. 
reported that for every 1% increase in ART availability, a 2% decrease in HIV incidence 
was observed in community settings in KwaZulu-Natal, South Africa [64]. In British 
Columbia, widespread availability of ART for people who inject drugs appears to have 
reduced HIV incidence as well [65]. It should be noted that four community-based clinical 
trials of TasP are underway [66].
There are further challenges to consider. First, unlinked transmissions from outside of the 
partnership (non-monogamy) are possible. Up to 27% of transmission events in the 
HPTN052 and Partners Study were attributable to external events [19, 67]. In a recent 
modeling study of extra-couple HIV transmission in sub-Saharan Africa, researchers 
estimated that 27 to 61% of all HIV infections among men and 21 to 51% of infections 
among women were attributable to extra-couple events [68]. Second, couples may not want 
to start ART early. For example, in a study of 1958 HIV-infected partners in Kenya and 
Uganda, 50.1% of those eligible for ART had not started therapy within six months of 
determined eligibility. Even at 24 months, 12.4% of those eligible still had not started 
therapy [69]. Third, successful TasP approaches require consistent high medication 
adherence – a constant challenge in practice. Fourth, there are concerns about behavioral 
risk compensation negating the prevention benefits of earlier ART initiation. A recent study 
among 957 participants in Cote d’Ivoire does not support this concern as no significant 
difference was found in sexual behavior risk among early versus standard initiators [70]. In 
addition, in the face of suppression of viral replication, risk behaviors are unlikely to result 
in HIV transmission [57].
TasP for MSM couples—The body of evidence and at least one new observational study 
suggest that TasP confers a similar prevention benefit to MSM serodiscordant couples [57, 
71]. The Partner Study is assessing the occurrence of linked transmission among 
serodiscordant heterosexual and MSM couples who have condomless sex, are not taking 
PrEP, and have a most recent viral load under 200 c/mL. Thus far, among 308 couple years 
of follow-up among MSM couples, no linked transmissions were observed [57]. The 
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Opposites Attract Study (running 2012 to 2015), is an observational cohort study enrolling 
MSM dyads in Australia, Brazil and Thailand (www.OppositesAttract.net.au). This study 
was designed to allow estimates for HIV transmission among partners on and not on ART, 
virally suppressed versus not virally suppressed, and practicing various levels of condomless 
anal intercourse.
Antiretroviral Pre-Exposure Prophylaxis (PrEP) (Table 2)
Pre-Exposure Prophylaxis (PrEP) refers to the provision of antiretrovirals to an uninfected 
person prior to exposure to HIV to prevent seroconversion following possible exposure. 
Thus far PrEP has been tested or is under development in the form of oral pills, vaginal/
rectal microbicides, and long-acting vaginal rings and intramuscular injectables [72, 73]. 
PrEP has been demonstrated to be effective at reducing HIV acquisition among both men 
and women in four RCTs [20, 74-76] (Table 2).
Oral PrEP—Using daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), the 
Pre-Exposure Prophylaxis Initiative (iPrEx) RCT among 2499 MSM found a 44% reduction 
in HIV incidence [75] while the TDF2 study among 1200 heterosexual men and women 
found a 63% reduction [76] and the Partners PrEP study among 4747 heterosexual 
serodiscordant couples found a 75% reduction [20]. In contrast, prevention benefit of oral 
TDF/FTC was not found in the Fem-PrEP [77] or the Vaginal and Oral Interventions to 
Control the Epidemic (VOICE) RCTs [78]. The most probable explanations for these 
divergent trial results have focused on suboptimal adherence. The U.S. FDA approved 
TDF/FTC (Truvada®) for use as PrEP in July 2012 and the U.S. CDC released new clinical 
practice guidelines for PrEP in May 2014 [79]. In brief, these guidelines focus on the 
recommended use of PrEP for sexually active MSM, heterosexual men and women, and 
injection drug users who are at “substantial risk of HIV acquisition” and the consideration of 
PrEP as “one of several options for serodiscordant heterosexual couples during conception 
and pregnancy”. NEXT-PrEP (HPTN-069) is assessing the safety of maraviroc for HIV-
negative people compared to TDF/FTC among MSM, heterosexual men and women and 
transgender men in 13 U.S. cities (http://www.nextprepstudy.org/).
Vaginal gel—The CAPRISA 004 study tested tenofovir 1% vaginal gel (TFV) used peri-
coitally among 889 heterosexual women at high risk of HIV infection and found a 39% 
reduction in infections overall and a 54% reduction among women who used at least 80% of 
prescribed doses [74]. Conversely, the VOICE trial (MTN-003) which tested daily TFV use 
among 5029 heterosexual women in HIV high prevalence areas was discontinued for futility 
[78]. The Follow-on African Consortium for Tenofovir Studies (FACTS) 001 trial is 
enrolling women age 18 to 30 across nine sites in South Africa for another trial of TVF. 
FACTS 001 (2015 anticipated trial completion) will assess the protective benefit of TFV 
applied pre and post-intercourse for HIV and HSV-2 prevention and FACTS 002 is in the 
planning phase for a similar trial among adolescent women age 16 – 17 (http://www.facts-
consortium.co.za/).
In development and testing—Numerous ongoing developments in PrEP science include 
testing new dosing regimens and new drugs for PrEP including dapivirine, rilpivirine, 
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maraviroc, and new integrase inhibitors (Table 2). Additionally, new drug formulations and 
delivery methods are under development, including gels, films, long-acting vaginal rings 
and injectables [72, 80]. Trials in Malawi are underway of the Dapivirine intravaginal ring 
(RING and ASPIRE – MTN020) [81]. Phase 1 trials are being conducted of long-acting 
injectables [82]. Five Phase I rectal microbicide trials have been completed in the U.S. and a 
Phase II trial (MTN017) will be conducted in the U.S., Peru, Thailand and South Africa to 
compare oral PrEP to TFV gel [83]. There are multipurpose prevention technologies under 
development that could provide combination protection against pregnancy, HIV, and HSV-2 
[84]. Finally, intermittent versus regular use of PrEP is also being studied [85]. Both dosing 
strategies have been shown to be safe, acceptable and able to achieve adherence in 
heterosexual couples [86] and MSM [87]. Prevention efficacy of intermittent PrEP is under 
investigation in at least two ongoing trials in the U.K. (PROUD) (http://
www.proud.mrc.ac.uk/) and France (IPERGAY) (http://www.ipergay.fr/).
PrEP for conception (PrEP-C)—Vernazza et al. described a strategy combining TasP 
and PrEP for safe conception among serodiscordant couples [88] (PrEP-C). A more recent 
study tested the use of PrEP with serodiscordant couples wishing to conceive naturally: 
Among 23 couples, TDF/FTC taken before and after timed ovulatory intercourse was safe 
and effective for preventing transmission during conception for serodiscordant couples 
where the male was HIV-positive and female was HIV-negative [89]. No transmission 
events were observed but further large-scale research is needed to validate the results.
Considerable barriers remain for the application of PrEP through primary care clinics. 
Knowledge and use of PrEP among providers is limited and education interventions are 
needed. Among doctors in American Academy of HIV Medicine surveyed in Sept 2011, 
although most were familiar with the results of PrEP studies (90%) and CDC guidelines 
(78%), only 19% had prescribed PrEP [90]. In a survey of 1175 infectious disease 
physicians in the U.S. and Canada, while the majority supported the use of PrEP, only 9% 
had prescribed it [91]. Physicians were most concerned about the real-world effectiveness of 
PrEP, adherence, risk compensation, toxicity, cost/reimbursement, moral issues, and drug 
resistance [91]. Much of data needed to address these concerns is (or will soon be) available. 
For example a sub-analysis of Partners PrEP data found no significant increase in STI, 
pregnancy or sexual risk taking behavior assessed before and after July 2011 when there was 
unmasking and knowledge of efficacy of PrEP for HIV prevention [92].
In general, people move in and out of lifestyles that put them at risk for HIV. Thus the 2014 
CDC PrEP guidelines for those “at substantial risk of HIV acquisition” are only a starting 
point for decisions in every-day clinical practice (not to mention the daily decisions that 
individual patients will make regarding their own self-assessment and interpretation of 
“substantial risk”). There are logical temporal situations that warrant short-term PrEP use, 
such as PrEP-C or for a new partnership until concordant HIV-negative status is confirmed, 
or until an HIV-positive partner is virally suppressed on ART.
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Use of monoclonal antibodies
Broadly neutralizing antibodies that form late in HIV infection also have potential to be used 
for HIV prevention. Several monoclonal broadly neutralizing antibodies have been 
described [93]. Moncolonal antibodies including VRC01 and PGT121 are entering safety 
trials with the idea that these antibodies might be used for PrEP or PEP (see below). In 
addition, Baltimore et al. have generated an adeno-associated virus (AAV) vector that can 
constitutively generate the PG9 monoclonal antibody [94]. This reagent can protect 
humanized mice from HIV infection. A similar construct has entered safety trials in Europe 
[95].
Non-occupational Post-Exposure Prophylaxis (nPEP)
Post-exposure Prophylaxis (PEP) refers to ARVs used soon after a high-risk exposure to 
HIV to avert infection. The U.S. Public Health Service issued guidelines for PEP in 1996 
which were updated in 2005 [96]. Although typically used for occupational exposures, PEP 
may be recommended following high-risk non-occupational exposures (nPEP) such as 
unprotected sex with a known or likely HIV positive partner, sexual assault, or injection 
drug use with a shared or used needle. nPEP is not recommended for those with recurrent 
HIV exposures, and thus is generally not used for preventing transmission among 
serodiscordant couples except in emergency cases (e.g. condom failure, rape). However, 
advances in PrEP technology may also offer new options for nPEP. For example, macaque 
studies found that a 1% Raltegravir gel applied vaginally three hours after exposure to SHIV 
prevented transmission in five out of six macaques and showed no evidence of developed 
drug resistance with repeated use [97].
Conclusion
Marked advances have been made in the past few years in HIV prevention for 
serodiscordant couples. However, a number of barriers and challenges remain. First, there is 
great need to scale-up CHTC and advance serodiscordant couples-based interventions, 
especially for MSM. Second, research is needed to understand how individuals and couples 
are adopting and adapting to the growing range of biomedical prevention tools (e.g. PrEP, 
TasP) and how best to promote and maintain use of these tools. Third, many remain unaware 
of the prevention benefits of ART and ART use faces continued barriers of concern about 
stigma and side-effects [98].
Adherence is a cross-cutting theme for the success of biomedical prevention efforts among 
serodiscordant couples and represents one of many examples of how biomedical and 
behavioral interventions must work in combination. Despite decades of knowledge about 
adherence barriers, facilitators and interventions [99, 100], optimal, sustained adherence 
remains elusive. There are only 10 CDC EBIs for HIV medication adherence, none of which 
are rated as “best-evidence” grading [33].
Combination approaches to HIV prevention show added benefit over individual strategies 
[101, 102] and are recommended by the WHO [103]. Combination prevention for 
serodiscordant couples can be implemented at the population level - for example through 
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policies and guidelines to support earlier initiation of ART - as well as at the individual 
level, such as combining TasP with medical male circumcision and CHTC. In fact, HPTN 
052 and the Partners PrEP studies were essentially combination prevention strategies: 
intensive couples counseling was provided along with a host of other benefits and incentives 
[104, 105].
Ultimately, all behaviorally acquired HIV transmission depends on risk behaviors within a 
serodiscordant couple. Focus on the prevention of HIV within these couples remains a 
critical consideration. Well-demonstrated reductions in risk of transmission reflect the 
results of intense investigation and critical RCTs. Complete reduction of transmission 
among serodiscordant couples is theoretically possible. Accordingly, residual transmission 
observed in recognized serodiscordant couples represents an important and resolvable 
challenge in HIV prevention.
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Table 1














couples assigned to early
or delayed therapy
Early ART was associated with a




2012 [106] Uganda 586
Serodiscordant
heterosexual couples.
Group A: CD4 ≥ 250
starting ART, Group B:
CD4 > 250, not yet on
ART
Transmission rate ratio comparing
those on ART vs. not on ART: 0.91
(95% CI, 0.38-2.20)
Bunnell et al.,





ART, prevention counseling, and
partner VCT associated w/ reduced
estimated risk of HIV transmission
during first 6 months of therapy
Del Romero et
al., 2010 [108] Spain 424
Couples recruited through
HIV+ patients at an
HIV/STI clinic
Heterosexual infectivity of HIV in













Provision of ART to HIV infected
patients could be an effective
strategy to achieve population-level
reductions in HIV transmission.
Hernando et al.,
2009 [110] Spain 339
HIV+ patients and their
partners attending a
HIV/STD clinic
Couples based safe sex counseling
and ART can reduce but not
eliminate sexual HIV transmission.
Melo et al.,
2008 [111] Brazil 93




higher median viral loads,
suggesting that heterosexual
transmission of HIV is more a
function of viral load than gender of
index case.
Reynolds et al.,
2011 [112] Uganda 250
Serodiscordant couples
offered free ART if
eligible
HIV transmission may be reduced
among HIV discordant couples after
initiation of ART due to reductions








Transmission rate of zero (95% CI:
0-0.40 per 100 years follow-up)
Upper limit 95% CI for transmission
for condomless anal sex: 0.96/100
(any); 1.97/100 (receptive anal sex






initiated on ART if
eligible
94% reduction in HIV transmission
ART associated with ART
Wang et al.,
2010 [114] China 1927
Former plasma donors
and their seronegative
Seroconversion rate of 1.71 per 100
person-years. No difference in rate
Lu et al., 2010
[115] spouses
of seroconversion between couples
who had a spouse on ART (4.8%)
vs. not on ART (3.2%) (p = 0.12).






























2005 [116] Spain 393
HIV clinic patients and
their seronegative
partners
Combined ART applied according to
current guidelines has a great
potential for preventing HIV
transmission to sexual partners.






26% relative reduction in HIV
transmission associated with ART
(adjusted hazard ratio 0.74, 95% CI
0.65-0.84)
Musicco et al.,




ART in HIV infected men reduces,
but does not eliminate, heterosexual
transmission of infection.
ART=antiretroviral therapy. STI = sexually transmitted infections. VCT = voluntary counseling and testing. HSV = herpes simplex virus.
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Table 2











































High TFV-DP concentrations in rectal tissue



















>30% did not complete study; cannot draw

































































Adherence assessment with monthly clinical
























High TFV-DP concentration in vaginal and









































For TDF, the tissue concentration may be critical;
for TFV 1% gel, adherence analysis is pending















































































































































































































































































Monthly tissue collection (colorectal,
cervicovaginal) for four months
TDF/FTC = tenofovir disoproxil fumarate/emtricitabine; TFV = tenofovir gel 1%; IPM = International Partnership for Microbicides; MTN = 
microbicide trails network; MWRI = ; RG = Raltegravir
Curr HIV/AIDS Rep. Author manuscript; available in PMC 2015 December 01.
